GlaxoSmithKline: Schizophrenia trials
The registry lists 23 Schizophrenia studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 1 have results posted.
Phase 1 15Phase 2 5Phase 3 2No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study to Evaluate the Efficacy and Safety of GSK239512 in SchizophreniaCompletedNCT01009060Phase 2Results posted
- First Time in Human Study (FTIH) With Positron Emission Tomography (PET)CompletedNCT01381419Phase 1
- A Study to Examine the Pharmacodynamic Effects of GSK1034702 on Neurophysiological Biomarkers of Cognition in Nicotine Abstained Otherwise Healthy SmokersCompletedNCT01371799Phase 1
- A Repeat Dose Positron Emission Tomography Study With GSK1144814CompletedNCT01209039Phase 1
- Pharmacokinetics, Effect of Food, Safety and Tolerability of a New Tablet Formulation of GSK1144814 in Healthy SubjectsCompletedNCT01090440Phase 1
- Positron Emission Tomography (PET) Study to Describe the Relationship Between Plasma Concentrations and Brain Gly-T1 Occupancy of GSK1018921 Over Time.CompletedNCT00945503Phase 1
- Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan StudyCompletedNCT00937846Phase 1
- A Repeat Dose Study With GSK1018921 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics in Healthy Volunteers and Patients With Schizophrenia and to Evaluate Its Effect on PK of Midazolam.TerminatedNCT00929370Phase 1
- Safety, Tolerability and Pharmacokinetics of GSK1034702 in Healthy SubjectsCompletedNCT00743405Phase 1
- First Time in Human Study With GSK1018921CompletedNCT00527020Phase 1
- A Healthy Volunteer Study to Assess the Relative Bioavailability of 2 Forms of SB773812 Tablets.CompletedNCT00500201Phase 1
- Evaluation of Single and Repeat Doses of GSK729327 in Healthy VolunteersCompletedNCT00448890Phase 1
- Effects Of The Drug Ketoconazole On How The Body Handles The Drug SB773812CompletedNCT00411866Phase 1
- A Study to Compare Two Different Brain Imaging Techniques in Healthy Volunteers and in Schizophrenic PatientsCompletedNCT00392743
- SPECT Investigation Of The NMDA Receptor System In Healthy Volunteers And Patients With SchizophreniaTerminatedNCT00364429Phase 1
- Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic PatientsCompletedNCT00300963Phase 2
- SPECT Study With SB-773812 In Schizophrenic PatientsCompletedNCT00269035Phase 1
- SB-773812 Administered In Adults With SchizophreniaCompletedNCT00259870Phase 2
- In-Patient Study In Schizophrenic PatientsCompletedNCT00197093Phase 1
- Study Of Talnetant Versus Placebo And Risperidone In SchizophreniaCompletedNCT00103727Phase 2
- Study Of An FDA-approved Drug As Additional Therapy In Patients With SchizophreniaCompletedNCT00086593Phase 3
- Clinical Study Of Schizophrenia in Both Men and WomenCompletedNCT00071747Phase 3
- Schizophrenia Study In AdultsCompletedNCT00049946Phase 2